Abstract: A blood measurement device (10) includes a light emitting part (11) that emits a light beam that is to transmit through a measurement site (18), a light receiving part (19) that receives the light beam that has transmitted through the measurement site (18), an integrating sphere part (14) interposed in an optical path along which the light beam emitted from the light emitting part (11) reaches the light receiving part (19), the integrating sphere part (14) having formed inside a reflection surface (26) that reflects the light beam, a light entry part (23) which is an opening provided at the integrating sphere part (14) and through which the light beam applied from the light emitting part (11) enters an inside of the integrating sphere part (14), and a light exit part (16) which is an opening provided at the integrating sphere part (14) and through which the light beam reflected by the reflection surface (26) of the integrating sphere part (14) is emitted from the integrating sphere part (14) toward the measur

Abstract: A blood measurement device (10) includes a light emitting part (11) that emits a light beam that is to transmit through a measurement site (18), a light receiving part (19) that receives the light beam that has transmitted through the measurement site (18), an integrating sphere part (14) interposed in an optical path along which the light beam emitted from the light emitting part (11) reaches the light receiving part (19), the integrating sphere part (14) having formed inside a reflection surface (26) that reflects the light beam, a light entry part (23) which is an opening provided at the integrating sphere part (14) and through which the light beam applied from the light emitting part (11) enters an inside of the integrating sphere part (14), and a light exit part (16) which is an opening provided at the integrating sphere part (14) and through which the light beam reflected by the reflection surface (26) of the integrating sphere part (14) is emitted from the integrating sphere part (14) toward the measur

Abstract: It is an object of the present invention to provide a therapeutic drug for carcinomatous peritonitis. According to the present invention, a therapeutic drug for carcinomatous peritonitis which comprises an antibody which recognizes a transferrin receptor, is provided.

Abstract: Provided is a blood measurement device capable of accurately estimating the amount of a component contained in blood by passing light beams for calculating the amount of the component contained in blood along the same optical axis. A blood measurement device 10 of the present invention includes a light emitting part 11 having a first light emitting part 111 and a second light emitting part 112, a light receiving part 19, an actuator 16, and a computation and control part 17 that estimates a glucose level and controls operation of the actuator 16.

Abstract: Provided is an implantable spacer that can be placed in a body and can be easily removed after placement. The implantable spacer includes a tube which is folded or bent at one or a plurality of positions to form partial sections adjacent to each other; fixing threads which are disposed along a direction transverse to the partial sections in order to maintain the shape of the tube; and a trigger thread for catching the fixing threads being in a releasable state.

Abstract: Provided is an implantable spacer that can be placed in a body and can be easily removed after placement. The implantable spacer includes a tube which is folded or bent at one or a plurality of positions to form partial sections adjacent to each other; fixing threads which are disposed along a direction transverse to the partial sections in order to maintain the shape of the tube; and a trigger thread for catching the fixing threads being in a releasable state.

Abstract: The present invention has been made with the aim to provide a surgical instrument, which can be put into a space between a peritoneum and muscle via a tunnel formed at the peritoneum easily and can be pulled strongly in a direction to peel the peritoneum from the muscle in hernia repair surgery or the like. A peritoneal peeling surgical instrument, which is put between muscle and a peritoneum via a tunnel formed at the peritoneum to peel the peritoneum from the muscle, includes: an operation part to be grasped and operated by the user; a shaft part connected with the operation part; a hinge part disposed at the tip of the shaft part; and a hook part connected with the shaft part via the hinge part. In response to operation to the operation part, the hook part is bent at the hinge part with respect to the shaft part and the bending state is fixed in one or more steps.

Abstract: The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent.

Abstract: The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent.

Abstract: The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent.

Abstract: The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent.

Abstract: The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent.

Abstract: The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent.

Abstract: The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent.